Whom are we treating with lipid-lowering drugs? Are we following the guidelines? Evidence from a population-based study: The Tromsø study 2001

European Journal of Clinical Pharmacology

Volumn 60, Issue 9, 2004, Pages 643-649

  Hartz, Ingeborg ^a   Eggen, Anne Elise ^a   Grimsgaard, Sameline ^a   Skjold, Frode ^a   Njølstad, Inger ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Guidelines; Lipid lowering drugs; Population based study

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL;

ADULT; AGED; CARDIOVASCULAR RISK; CLINICAL PROTOCOL; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DRUG SURVEILLANCE PROGRAM; DRUG USE; DRUG UTILIZATION; FEMALE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NORWAY; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SELF REPORT; SEX DIFFERENCE;

ADULT; AGE FACTORS; AGED; ANTILIPEMIC AGENTS; CHOLESTEROL; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; DRUG UTILIZATION; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LOGISTIC MODELS; MALE; MIDDLE AGED; NORWAY; PRACTICE GUIDELINES; QUESTIONNAIRES; RISK FACTORS; SEX FACTORS;

EID: 11244311754     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-004-0827-z     Document Type: Review

References (40)

1. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 344:1383-1389
2. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 335:1001-1009
3. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349-1357
4. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW et al (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333:1301-1307
5. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA et al (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas coronary atherosclerosis prevention study. JAMA 279:1615-1622
6. Wesenberg G (ed) (2000) Treatment recommendations for hyperliperlipidemia. Norwegian Medicines Agency, Oslo
7. Pedersen JI, Tverdal A, Kirkhus B (2004) Diet and the rise and fall of cardiovascular disease mortality in Norway. Tidsskr Nor Laegeforen 124:1532-1536
8. Rønning M (2003) Drug Consumption in Norway 1998-2002. WHO collaborating centre for drug statistics and methodology, Oslo
9. Nordic Medico-Statistical Committee (NOMESCO) (2003) Health statistics in the nordic countries 2001. NOMESCO, Copenhagen
10. Dubois RW, Alexander CM, Wade S, Mosso A, Markson L, Lu JD et al (2002) Growth in use of lipid-lowering therapies: are we targeting the right patients? Am J Manag Care 8:862-867
11. Savoie I, Kazanjian A (2002) Utilization of lipid-lowering drugs in men and women. A reflection of the research evidence? J Clin Epidemiol 55:95-101
12. Magrini N, Einarson T, Vaccheri A, McManus P, Montanaro N, Bergman U (1997) Use of lipid-lowering drugs from 1990 to 1994: an international comparison among Australia, Finland, Italy (Emilia Romagna Region), Norway and Sweden. Eur J Clin Pharmacol 53:185-189
13. Svilaas A, Thoresen M, Kristoffersen JE, Hjartaaker J, Westheim A (2000) How well are patients with atherosclerotic disease treated? Secondary prevention in primary care. Scand J Prim Health Care 18:232-236
14. Notø AT, Steffensen L, Nordøy A, Hansen JB (2001) Use of statins in hospitals after myocardial infarction. Tidsskr Nor Laegeforen 121:2467-2471
15. EUROASPIRE II Study Group (2001) Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 22:554-572
16. Abookire SA, Karson AS, Fiskio J, Bates DW (2001) Use and monitoring of 'statin' lipid-lowering drugs compared with guidelines. Arch Intern Med 161:53-58
17. Primatesta P, Poulter NR (2000) Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ 321:1322-1325
18. Reid FD, Cook DG, Whincup PH (2002) Use of statins in the secondary prevention of coronary heart disease: is treatment equitable? Heart 88:15-19
19. Lemaitre RN, Furberg CD, Newman AB, Hulley SB, Gordon DJ, Gottdiener JS et al (1998) Time trends in the use of cholesterol-lowering agents in older adults: the cardiovascular health study. Arch Intern Med 158:1761-1768
20. Hoerger TJ, Bala MV, Bray JW, Wilcosky TC, LaRosa J (1998) Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am J Cardiol 82:61-65
21. Municipal administration of Tromsø (ed) (1996) Figures and facts (Kalde tall og harde fakta). Tromsø, Norway
22. Engstad T, Bønaa KH, Viitanen M (2000) Validity of self-reported stroke: The Tromsø Study. Stroke 31:1602-1607
23. Wilsgaard T (2002) Longitudinal analysis of cardiovascular risk factors. Thesis, University of Tromsø, Tromsø
24. World Health Organization (1997) Obesity. Preventing and managing the global epidemic. Report of a WHO consultation on obesity. WHO, Geneva
25. Friedewald W, Levy R, Frederickson D (1997) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultra-centrifuge. Clin Chem 18:499-501
26. World Health Organization (1999) International society of hypertension guidelines for the management of hypertension (Guidelines subcommittee). J Hypertens 17:151-183
27. Jackevicius CA, Mamdani M, Tu JV (2002) Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 288:462-467
28. Svilaas A, Risberg K, Thoresen M, Ose L (2000) Lipid treatment goals achieved in patients treated with statin drugs in Norwegian general practice. Am J Cardiol 86:1250-1253
29. Hippisley-Cox J, Cater R, Pringle M, Coupland C (2003) Cross sectional survey of effectiveness of lipid lowering drugs in reducing serum cholesterol concentration in patients in 17 general practices. BMJ 326:689-694
30. Jones P, Kafonek S, Laurora I, Hunninghake D (1998) Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 81:582-587
31. Barter PJ, O'Brien RC (2000) Achievement of target plasma cholesterol levels in hypercholesterolaemic patients being treated in general practice. Atherosclerosis 149:199-205
32. Midthjell K, Holmen J, Bjørndal A, Lund Larsen G (1992) Is questionnaire information valid in the study of a chronic disease such as diabetes? The Nord-Trøndelag diabetes study. J Epidemiol Community Health 46:537-542
33. Tretli S, Lund Larsen PG, Foss OP (1982) Reliability of questionnaire information on cardiovascular disease and diabetes: cardiovascular disease study in Finnmark county. J Epidemiol Community Health 36:269-273
34. Kehoe R, Wu SY, Leske MC, Chylack LT Jr (1994) Comparing self-reported and physician-reported medical history. Am J Epidemiol 139:813-818
35. Lampe FC, Walker M, Lennon LT, Whincup PH, Ebrahim S (1999) Validity of a self-reported history of doctor-diagnosed angina. J Clin Epidemiol 52:73-81
36. Paganini Hill A, Ross RK (1982) Reliability of recall of drug usage and other health-related information. Am J Epidemiol 116:114-122
37. Klungel OH, de Boer A, Paes AH, Herings RM, Seidell JC, Bakker A (1999) Agreement between self-reported antihypertensive drug use and pharmacy records in a population-based study in The Netherlands. Pharm World Sci 21:217-220
38. Muhlestein JB, Horne BD, Bair TL, Li Q, Madsen TE, Pearson RR et al (2001) Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol 87:257-261
39. Lacy CR, Suh DC, Barone JA, Bueno M, Moylan D, Swartz C et al (2002) Impact of a targeted intervention on lipid-lowering therapy in patients with coronary artery disease in the hospital setting. Arch Intern Med 162:468-473
40. Tsuyuki RT, Johnson JA, Teo KK, Simpson SH, Ackman ML, Biggs RS et al (2002) A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the study of cardiovascular risk intervention by pharmacists (SCRIP). Arch Intern Med 162:1149-1155